Departamento de Medicina Interna, Hospital La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain.
Departamento de Medicina Interna, Hospital La Mancha Centro, Alcázar de San Juan, Ciudad Real, Spain.
Med Clin (Barc). 2022 Dec 23;159(12):557-562. doi: 10.1016/j.medcli.2022.02.025. Epub 2022 Jun 17.
Treating systemic inflammation caused by SARS-COV 2 (COVID-19) has become a challenge for the clinician. Corticosteroids have been the turning point in the treatment of this disease. Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone at doses of 6mg/day shows a reduction on morbidity in patients requiring added oxygen therapy. However, both the start day or what kind of corticosteroid, are still questions to be clarified. Since the pandemic beginning, we have observed large differences in the type of corticosteroid, dose and initiation of treatment. Our objective is to assess the predictive capacity of the characteristics of patients treated with methylprednisolone pulses to predict hospital discharge.
We presented a one-center observational study of a retrospective cohort. We included all patients admitted between 03/06/2020 and 05/15/2020 because of COVID-19. We have a total number of 1469 patients, of whom 322 received pulses of methylprednisolone. Previous analytical, radiographic, previous disease data were analyzed on these patients. The univariant analysis was performed using Chi-squared and the T test of Student according to the qualitative or quantitative nature of the variables respectively. For multivariate analysis, we have used binary logistic regression and ROC curves.
The analysis resulted statistically significant in dyspnea, high blood pressure, dyslipidemia, stroke, ischemic heart disease, cognitive impairment, solid tumor, C-reactive protein (CRP), lymphopenia and d-dimer within 5 days of admission. Radiological progression and FIO input are factors that are associated with a worst prognosis in COVID-19 that receive pulses of methylprednisolone. Multivariate analysis shows that age, dyspnea and C-reactive protein are markers of hospital discharge with an area below the curve of 0.816.
In patients with methylprednisolone pulses, the capacity of the predictive model for hospital discharge including variables collected at 5 days was (area under the curve) 0.816.
治疗由 SARS-COV 2(COVID-19)引起的全身炎症已成为临床医生的挑战。皮质类固醇一直是治疗这种疾病的转折点。Recovery 临床试验的初步数据带来了希望,表明每天 6mg 剂量的地塞米松治疗可降低需要吸氧治疗的患者的发病率。然而,开始治疗的时间或使用哪种皮质类固醇,仍有待澄清。自大流行开始以来,我们观察到皮质类固醇的类型、剂量和开始治疗的差异很大。我们的目的是评估接受甲基强的松龙脉冲治疗的患者的特征预测住院出院的能力。
我们提出了一项回顾性队列的单中心观察性研究。我们纳入了所有 2020 年 3 月 6 日至 2020 年 5 月 15 日期间因 COVID-19 入院的患者。我们共有 1469 名患者,其中 322 名患者接受了甲基强的松龙脉冲治疗。对这些患者进行了先前的分析、放射学、先前疾病数据的分析。使用卡方检验和学生 t 检验分别根据变量的定性或定量性质进行单变量分析。对于多变量分析,我们使用二元逻辑回归和 ROC 曲线。
分析结果显示,入院后 5 天内呼吸困难、高血压、血脂异常、中风、缺血性心脏病、认知障碍、实体瘤、C 反应蛋白(CRP)、淋巴细胞减少和 D-二聚体有统计学意义。放射学进展和 FIO 输入是与 COVID-19 接受甲基强的松龙脉冲治疗预后较差相关的因素。多变量分析显示,年龄、呼吸困难和 C 反应蛋白是预测出院的标志物,曲线下面积为 0.816。
在接受甲基强的松龙脉冲治疗的患者中,包括在 5 天内收集的变量的预测模型出院能力(曲线下面积)为 0.816。